Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Clin Neurophysiol. 2017 Dec 1;129(1):188–197. doi: 10.1016/j.clinph.2017.10.019

TABLE 1.

Patient profile.

Number of patients 63
Mean age (year old) 13.5
Range of age (year old) 4 – 44
Proportion of male (%) 49.2
Sampled hemisphere. Number of patients (%)
 Left alone 25 (39.7)
 Right alone 28 (44.4)
 Both 10 (15.9)
Seizure onset zone. Number of patients (%)
 involving Frontal 12 (19.0)
 involving Temporal 33 (52.4)
 involving Parietal 16 (25.4)
 involving Lateral-Occipital 4 (6.3)
Mean number of antiepileptic drugs 1.9
Antiepileptic drugs. Number of patients (%)
 Carbamazepine (CBZ) 4 (6.3)
 Oxcarbazepine (OXC) 30 (47.6)
 Lacosamide (LCM) 20 (31.7)
 Zonisamide (ZNS) 4 (6.3)
 Phenytoin (PHT) 2 (3.2)
 Lamotrigine (LTG) 18 (28.6)
 Levetiracetam (LEV) 24 (38.1)
 Valproate (VPA) 8 (12.7)
 Clobazam (CLB) 5 (7.9)
 Topiramate (TPM) 2 (3.2)
Etiology. Number of patients (%)
 Tumor 12 (19.0)
 Dysplasia 21 (33.3)
 Hippocampal sclerosis 6 (9.5)
 Dysplasia + Hippocampal sclerosis 1 (1.6)
 No definitive lesion other than gliosis 22 (34.9)
 Arteriovenous malformation 1 (1.6)

Ten patients had seizure onset zones involving at least two lobes.